Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIIc Clinical Study Evaluating the Long-term Treatment of Hepatic Fibrosis in Chronic Hepatitis B With Hydronidone Capsules.

NCT07412236 is registered in ClinicalTrials.gov with Beijing Continent Pharmaceutical Co, Ltd. as lead sponsor.

NCT NCT07412236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07412236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIIc Clinical Study Evaluating the Long-term Treatment of Hepatic Fibrosis in Chronic Hepatitis B With Hydronidone Capsules.
Lead sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 30, 2026
Completion date
December 30, 2028
Enrollment
1,208 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver fibrosis, liver fibrosis in chronic hepatitis b